The value of PSA screenings
Research to test the predictive value of prostate cancer screenings for Black men in the United States has found that a single baseline prostate-specific antigen (PSA) screening during midlife strongly predicts risk of total and aggressive cancer in members of this cohort for up to 12 years. The study, say HMS researchers at Brigham and Women’s Hospital and Harvard T.H. Chan School of Public Health, is the first to address whether an optimized screening strategy with baseline PSA levels predicts prostate cancer in this population. U.S. Black men are more likely to be diagnosed with, and 2.5 times more likely to die of, prostate cancer than their white counterparts.
Preston MA, et al., European Urology, September 2018
Image: Izzat Suffian, David McCarthy, Khuloud T. al-Jamal/Wellcome